DDInter917 DDInter1628
A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem]
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Indinavir {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Indinavir {u} (Compound) downregulates {v} (Gene) PRPF4
PRPF4 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Indinavir {u} (Compound) downregulates {v} (Gene) CHMP4A
CHMP4A {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Indinavir {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Indinavir {u} (Compound) downregulates {v} (Gene) PRPF4
PRPF4 {u} (Gene) is regulated by {v} (Gene) LTK
LTK {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Indinavir {u} (Compound) downregulates {v} (Gene) HDGFRP3
HDGFRP3 {u} (Gene) is downregulated by {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Indinavir {u} (Compound) downregulates {v} (Gene) PSMG1
PSMG1 {u} (Gene) is regulated by {v} (Gene) RPP38
RPP38 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Indinavir {u} may lead to a major life threatening interaction when taken with {v} Nilotinib
Nilotinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Indinavir {u} (Compound) downregulates {v} (Gene) PSMG1
PSMG1 {u} (Gene) is regulated by {v} (Gene) AKT1
AKT1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Indinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Bortezomib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Indinavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Indinavir (Compound) downregulates PRPF4 (Gene) and PRPF4 (Gene) is upregulated by Ruxolitinib (Compound)
Indinavir (Compound) downregulates CHMP4A (Gene) and CHMP4A (Gene) is downregulated by Ruxolitinib (Compound)
Indinavir (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Indinavir (Compound) downregulates PRPF4 (Gene) and PRPF4 (Gene) is regulated by LTK (Gene) and LTK (Gene) is bound by Ruxolitinib (Compound)
Indinavir (Compound) downregulates HDGFRP3 (Gene) and HDGFRP3 (Gene) is downregulated by hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Indinavir (Compound) downregulates PSMG1 (Gene) and PSMG1 (Gene) is regulated by RPP38 (Gene) and RPP38 (Gene) is upregulated by Ruxolitinib (Compound)
Indinavir may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Indinavir (Compound) downregulates PSMG1 (Gene) and PSMG1 (Gene) is regulated by AKT1 (Gene) and AKT1 (Gene) is downregulated by Ruxolitinib (Compound)
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)